Lumazine synthase catalyzes, the condensation of 5-amino-6-(D-ribitylamino)-2,4-(1H,3H)pyrimidinedione with the novel carbohydrate, L-3,4-dihydroxy-2-butanone-4-phosphate to form the immediate precursor to riboflavin, 6,7-dimethyl-8-(D-ribitylamino)lumazine. Recent developments in our understanding of lumazine synthase include the identification of L-3,4-dihydroxy-2-butanone-4-phosphate as one of the substrates, and the X-ray structure of reconstituted beta 60 capsids of lumazine synthase complexed with 5-(6-D-ribitylamino-2,4-dihydroxypyrimidin-5-yl)-1-pentylphosphonic acid, a metabolically stable analog of the hypothetical Schiff base intermediate in the enzyme-catalyzed reaction. The identification of the carbohydrate precursor has allowed a mechanistic hypothesis to be advanced concerning the pathway for the conversion of the substrates into the lumazine product. In addition, the X-ray structure has made it possible to propose a mechanism for how the enzyme functions, as well as a hypothetical binding geometry for the substrates and proposed reaction intermediates. In order to test these new ideas, metabolically stable analogs of the hypothetical reaction intermediates are required. The present research project involves the design and synthesis of a set of metabolically stable reaction intermediate analogs that will be valuable in obtaining evidence about the structural and mechanistic details of lumazine synthase catalysis, including protein and ligand mobility during the catalytic event. These ligands will be bound to the active site of lumazine synthase by ligand driven aggregation or by diffusion and the X-ray structures of the resulting complexes will be determined. The distances of certain atoms of the ligands to 15N nuclei of the protein will be determined to within 0.2 A by REDOR NMR, and these distances will be used in combination with the X-ray crystal coordinates in a series of distance-restrained molecular dynamics simulations to obtain a binding model for each ligand. All potential mutations of the protein can be made by site-directed mutagenesis, and the recombinant protein expressed in E. coli. The mechanistic interpretation will be based on protein as well as ligand modifications. Uniformly 15N-labeled protein and fluorine-containing protein will be especially useful in the interpretation of the REDOR spectra. The recent identification of L-3,4-dihydroxy-2-butanone-4-phosphate as a substrate of lumazine synthase has made it possible to determine the standard thermodynamic and kinetic parameters of lumazine synthase inhibitors. The inhibition constants (Ki) and dissociation constants (Kd) of the new inhibitors will be determined, and ligand displacement studies will also be performed. The binding stochiometry will be determined. These experiments will be performed on both hollow beta 60 capsids and heavy riboflavin synthase.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM051469-05A1
Application #
6095921
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Jones, Warren
Project Start
1995-08-01
Project End
2004-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
5
Fiscal Year
2000
Total Cost
$215,500
Indirect Cost
Name
Purdue University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Talukdar, Arindam; Zhao, Yujie; Lv, Wei et al. (2012) O-Nucleoside, S-nucleoside, and N-nucleoside probes of lumazine synthase and riboflavin synthase. J Org Chem 77:6239-61
Morgunova, Ekaterina; Illarionov, Boris; Saller, Sabine et al. (2010) Structural study and thermodynamic characterization of inhibitor binding to lumazine synthase from Bacillus anthracis. Acta Crystallogr D Biol Crystallogr 66:1001-11
Kim, Ryu-Ryun; Illarionov, Boris; Joshi, Monika et al. (2010) Mechanistic insights on riboflavin synthase inspired by selective binding of the 6,7-dimethyl-8-ribityllumazine exomethylene anion. J Am Chem Soc 132:2983-90
Talukdar, Arindam; Morgunova, Ekaterina; Duan, Jianxin et al. (2010) Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthase. Bioorg Med Chem 18:3518-34
Zhao, Yujie; Bacher, Adelbert; Illarionov, Boris et al. (2009) Discovery and development of the covalent hydrates of trifluoromethylated pyrazoles as riboflavin synthase inhibitors with antibiotic activity against Mycobacterium tuberculosis. J Org Chem 74:5297-303
Talukdar, Arindam; Breen, Meghan; Bacher, Adelbert et al. (2009) Discovery and development of a small molecule library with lumazine synthase inhibitory activity. J Org Chem 74:5123-34
Yu, Tsyr-Yan; O'Connor, Robert D; Sivertsen, Astrid C et al. (2008) (15)N{(31)P} REDOR NMR studies of the binding of phosphonate reaction intermediate analogues to Saccharomyces cerevisiae lumazine synthase. Biochemistry 47:13942-51
Zhang, Yanlei; Illarionov, Boris; Morgunova, Ekaterina et al. (2008) A new series of N-[2,4-dioxo-6-d-ribitylamino-1,2,3,4-tetrahydropyrimidin-5-yl]oxalamic acid derivatives as inhibitors of lumazine synthase and riboflavin synthase: design, synthesis, biochemical evaluation, crystallography, and mechanistic implications. J Org Chem 73:2715-24
Zhang, Yanlei; Illarionov, Boris; Bacher, Adelbert et al. (2007) A novel lumazine synthase inhibitor derived from oxidation of 1,3,6,8-tetrahydroxy-2,7-naphthyridine to a tetraazaperylenehexaone derivative. J Org Chem 72:2769-76
Kaiser, Johannes; Illarionov, Boris; Rohdich, Felix et al. (2007) A high-throughput screening platform for inhibitors of the riboflavin biosynthesis pathway. Anal Biochem 365:52-61

Showing the most recent 10 out of 36 publications